Skip to main content
SpringerLink
Log in

Use of Integrase Inhibitors in HIV-Infected Children and Adolescents

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Resistance to antiretroviral drugs is an increasingly prevalent challenge affecting both the adult and pediatric HIV-infected populations. Though data on the safety, pharmacokinetics, and efficacy of newer antiretroviral agents in children typically lags behind adult data, newer agents are becoming available for use in HIV-infected children who are failing to respond to or are experiencing toxicities with traditional antiretroviral regimens. Integrase strand transfer inhibitors are one such new class of antiretrovirals. Raltegravir has been US Food and Drug Administration (FDA) approved for use in patients over the age of 4 weeks. Elvitegravir is a second member of this class, and has the potential for use in children but does not yet have a Pediatric FDA indication. Dolutegravir, a second-generation integrase inhibitor, is approved for those older than 12 years. This review summarizes the use of integrase inhibitors in children and adolescents, and highlights the results of recent clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. UNAIDS. The gap report. 2015. http://www.unaids.org/en/resources/documents/2014/20140716_UNAIDS_gap_report. Accessed 3 Apr 2015.

  2. United States National Institutes of Health. Global HIV/AIDS overview. 2014. http://www.aids.gov/federal-resources/around-the-world/global-aids-overview. Accessed 28 Mar 2015.

  3. Abrams E, Weedon J, Steketee R, Lambert G, Bamji M, Brown T. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. J Infect Dis. 1998;178(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  4. Sandberg J, Fast N, Jordan K, Furlan S, Barbour J, Fennelly G. HIV-specific CD8+ T-cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol. 2003;170:4403–10.

    Article  CAS  PubMed  Google Scholar 

  5. DeLaugerre C, Warszawski J, Chaix M, Veber F, Macassa E, Buseyne F. Prevalence and risk factors associated with antiretroviral resistance in HIV-1 infected children. J Med Virol. 2007;79:1261–9.

    Article  PubMed  Google Scholar 

  6. Chandwani S, Keonig L, Sill A, Abramowitz S, Conner L, D’Angelo L. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health. 2012;51(3):242–51.

    Article  PubMed  Google Scholar 

  7. Menson E, Walker A, Sharland M, Wells C, Tudor-Williams G, Riordan F. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study. BMJ. 2006;332(7551):1183–7.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Martino MD, Tovo P, Balducci M, Galli L, Gabiano C, Rezza G. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284(2):190–7.

    Article  PubMed  Google Scholar 

  9. Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi S. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Hazuda D, Felock P, Wimter M, Wolfe A, Stillmock K, Grobler J. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–50.

    Article  CAS  PubMed  Google Scholar 

  11. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown K, Ferris R. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Hare S, Smith S, Metifot M, Jaxa-Chamiec A, Pommier Y, Hughes S. Structural and functional analyses of the second-generation integrase strant transfer inhibitor dolutegravir. Mol Pharmacol. 2011;80:565–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51.

    Article  CAS  PubMed  Google Scholar 

  14. Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, et al. Examination of non-inferiority, safety and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the PROGRESS study, 48-week results. HIV Clin Trials. 2011;12(5):255–67.

    Article  CAS  PubMed  Google Scholar 

  15. Nachman S, Zheng N, Acosta E, Teppler H, Bomony B, Graham B. Pharmacokinetics, safety and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014;58(3):413–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Viani RM, Alvero C, Fenton T, Acosta E, Hazra R, Townley E, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015 (in press).

  17. Steigbigel R, Cooper D, Kumar P, Eron J, Schechter M, Markowitz M. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–54.

    Article  PubMed  Google Scholar 

  18. Lennox J, Dejesus E, Lazzarin A, Pollard R, Madruga J, Berger D. Safety and efficacy of raltegravir-based versus efavirenz based combination therapy in treatment-naive patients with HIV-1 infection: a multi-centre, double-blind randomized controlled trial. Lancet. 2009;374:796–806.

    Article  CAS  PubMed  Google Scholar 

  19. United States Food and Drug Administration. FDA approval of Isentress (raltegravir). 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm284473.htm. Accessed 2 Apr 2015.

  20. Steigbigel R, Cooper D, Teppler H, Eron J, Gatell J, Kumar P. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50:605–12.

    Article  CAS  PubMed  Google Scholar 

  21. Eron JJ, Cooper D, Steigbigel R, Clotet B, Gatell J, Kumar P. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomized, placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587–96.

    Article  CAS  PubMed  Google Scholar 

  22. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retrovir. 2013;29(2):256–65.

    CAS  PubMed  Google Scholar 

  23. Gotuzzo E, Markowitz M, Ratanasuwan W, Smith G, Prada G, Morales-Ramirez J. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr. 2012;61(1):73–8.

    Article  CAS  PubMed  Google Scholar 

  24. Temesgen Z, Siraj D. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag. 2008;4(2):493–500.

    PubMed Central  CAS  PubMed  Google Scholar 

  25. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657–63.

    Article  CAS  PubMed  Google Scholar 

  26. Wenning L, Hanley W, Brainard D, Petry A, Ghosh K, Jin B, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. United States Food and Drug Administration. Isentress Package Insert. 2011. http://www.access.data.fda.gov/drugsatfda_docs/label/2011/022145s018lbl.pdf. Accessed 3 Apr 2015.

  28. Stellbrink H. Raltegravir in the management of HIV-infected patients. Drug Des Devel Ther. 2008;2:281–8.

    Article  PubMed Central  CAS  Google Scholar 

  29. Adams J, Greener B, Kashuba A. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):390–400.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Jackson A, Watson V, Back D, Khoo S, Liptrott N, Egan D. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-1 infected individuals. J Acquir Immune Defic Syndr. 2011;58(5):450–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Hanley W, Wenning L, Moreau A, Kost J, Mangin E, Shamp T. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2752–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C, Yeni P. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–65.

    Article  CAS  PubMed  Google Scholar 

  33. Brainard D, Wenning L, Stone J, Wagner J, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol. 2011;51:1376–402.

    Article  CAS  PubMed  Google Scholar 

  34. Eron J, Rockstroh J, Reynes J, Andrade-Villanueva J, Ramalho-Madruga J, Bekker L. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial. Lancet. 2011;11:907–16.

    Article  CAS  PubMed  Google Scholar 

  35. Eron J, Young B, Cooper D, Youle M, DeJesus E, Andrada-Villanueva J. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viremia (SWITCHMRK 1 and 2): two multi-centre, double-blind, randomized controlled trials. Lancet. 2010;375:396–408.

    Article  CAS  PubMed  Google Scholar 

  36. Thuret I, Chaix M, Tamalet C, Reliquet V, Firtion G, Tricoire J. Raltegravir, etravirine and r-darunavir combination in adolescents with multi-drug-resistant virus. AIDS. 2009;23(17):2364–6.

    Article  CAS  PubMed  Google Scholar 

  37. Briz V, Leon-Leal J, Palladino C, Moreno-Perez D, de Ory S, De Jose I. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J. 2012;31(3):273–7.

    Article  PubMed  Google Scholar 

  38. Nachman S, Alvero C, Acosta E, Teppler H, Homony B, Graham B, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. J Pediatric Infect Dis Soc. doi:10.1093/jpids/piu146 (Epub 7 Feb 2015).

  39. Johnson V, Calvez V, Gunthard H, Paredes R, Pillay D, Shafer R. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6–15.

    PubMed  Google Scholar 

  40. Canducci F, Sampaolo M, Marinozzi M, Boeri E, Spagnuolo V, Galli A. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009;23:455–60.

    Article  CAS  PubMed  Google Scholar 

  41. Canducci F, Marinozzi M, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother. 2010;65:425–33.

    Article  CAS  PubMed  Google Scholar 

  42. Cahn P, Pazniak A, Mingrone H, Chuldyakov A, Brites C, Andrade-Villanueva J. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase inhibitor naive adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–8.

    Article  CAS  PubMed  Google Scholar 

  43. European Medicines Agency. Isentress (raltegravir). 2009. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000860/human_med_000859.jsp&mid=WC0b01ac058001d124. Accessed 2 Jul 2015.

  44. The Medicines Patent Pool (MPP). The Medicines Patent Pool signs licensing agreement with MSD for paediatric formulations of raltegravir. 2015. http://www.medicinespatentpool.org/the-medicines-patent-pool-signs-licensing-agreement-with-msd-for-paediatric-formulations-of-raltegravir/. Accessed 2 Jul 2015.

  45. Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014;371(3):234–47.

    Article  PubMed  Google Scholar 

  46. Karmon S, Markowitz M. Next-generation integrase inhibitors: where to after raltegravir? Drugs. 2013;73:213–28.

    Article  CAS  PubMed  Google Scholar 

  47. Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012;21:395–401.

    Article  CAS  PubMed  Google Scholar 

  48. Gilead. Package insert Stibild. http://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf?la=en. Accessed 10 Jul 2015.

  49. United States Food and Drug Administration. FDA approves new drug to treat HIV infection. 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Accessed 3 Apr 2015.

  50. Custodio JM, Rhee M, Shen G, Ling KHJ, Kearney BP, Ramanathan S. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment. Antimicrob Agents Chemother. 2014;58:2564–9.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Ramanathan S, Mathias A, Wei X, Shen G, Koziara J, Cheng A, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64:45–50.

    Article  CAS  PubMed  Google Scholar 

  52. Reviriego C. Elvitegravir for the treatment of HIV infection. Drugs Today. 2014;50:209–17.

    Article  CAS  PubMed  Google Scholar 

  53. Shah B, Schafer J, Priano J, Squires K. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013;33:1107–16.

    Article  CAS  PubMed  Google Scholar 

  54. United States Food and Drug Administration. Package insert, Vitekta. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203093s000lbl.pdf. Accessed 3 Apr 2015.

  55. Ramanathan S, Abel S, Tweedy S, West S, Hui J, Kearney BP. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defec Syndr. 2010;53(2):209–14.

    Article  CAS  Google Scholar 

  56. Lee F, Carr A. Tolerability of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7:422–8.

    Article  CAS  PubMed  Google Scholar 

  57. Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, DeJesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e118–21.

    Article  PubMed  Google Scholar 

  58. Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, et al. Double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e121–4.

    Article  PubMed  Google Scholar 

  59. Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014;14:590–9.

    Article  CAS  PubMed  Google Scholar 

  60. Custodio JM, Liu Y, Graham H, Hepner M, Wiser L, Quirk E, et al. Bioequivalence of two pediatric formulations vs adult tablet formulation of elvitegravir [abstract no. 902]. 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.

  61. Custodio JM, Liu Y, Graham H, Hepner M, Koziara J, Quirk E, et al. Bioequivalence of two pediatric formulations vs adult tablet formulation of cobicistat [abstract no. 908]. 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.

  62. Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Lawson E, Shao Y, et al. Safety, efficacy and pharmacokinetics of the integrase inhibitor-based E/C/F/TAF single-tablet regimen in treatment-naïve HIV-infected adolescents through 24 weeks of treatment [poster no. 953]. Conference on Retroviruses and Opportunistic Infections; 23–26 Feb 2015; Seattle.

  63. Gaur A, Fourie J, Chokephaibulkit K, Bekker LG, Yin X, Custodio JM, et al. Pharmacokinetics, efficacy, and safety of an integrase inhibitor STR in HIV-infected adolescents [abstract no. 909]. 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.

  64. Custodio JM, Musiime V, Gaur A, MsFarland E, Prasitsuebsai W, Hellstrom L, et al. Pharmacokinetics and preliminary safety of elvitegravir in HIV-1 infected pediatric subjects [abstract no. 951]. 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.

  65. Gilead Sciences. Pharmacokinetics, safety, and efficacy of elvitegravir/cobicistat/emtricitibine/tenofovir disoproxil fumarate single tablet regimen (STR) in adolescents [ClinicalTrials.gov identifier NCT01721109]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 3 Apr 2015.

  66. Gilead Sciences. Pharmacokinetics, safety, and antiviral activity of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment-naive adolescents and virologically suppressed children [ClinicalTrials.gov identifier NCT01854775]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 3 Apr 2015.

  67. Gilead Sciences. Two part study to study pharmacokinetics, safety, and antiviral activity of elvitegravir (EVG) administered with a PI/r background regimen for ARV treatment-experienced pediatric subjects. [ClinicalTrials.gov identifier NCT01923311]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 3 Apr 2015.

  68. Quashie P, Mesplede T, Wainberg M. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis. 2013;26:43–9.

    CAS  PubMed  Google Scholar 

  69. European Medicines Agency. Vitekta (elvitegravir). 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002577/human_med_001710.jsp&mid=WC0b01ac058001d124. Accessed 2 Jul 2015.

  70. The Medicines Patent Pool (MPP). MPP licence on elvitegravir (EVG). 2011. http://www.medicinespatentpool.org/mpp-licence-on-elvitegravir-evg/. Accessed 2 Jul 2015.

  71. Oliveira MF, Ramalho DB, Abreu CM, Vubil A, Mabunda N, Ismael N, et al. Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors. AIDS Res Hum Retrovir. 2012;28(12):1788–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M, AC11/AC12 ANRS Working Group. Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naïve patients from sub-Saharan countries and discordant interpretations. AIDS Res Hum Retrovir. 2012;28(9):1157–60.

    CAS  PubMed  Google Scholar 

  73. Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE, Toure M, et al. HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. PLoS One. 2011;6(7):e22204.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retrovir. 2010;26(4):489–93.

    Article  CAS  PubMed  Google Scholar 

  75. Hightower K, Wang R, Deanda F, Johns B, Weaver K, Shen Y. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Underwood M, Johns B, Sato A, Martin J, Deeks S, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012;61(3):297–301.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. van Lunzen J, Maggiolo F, Arribas J, Rakhmanaova A, Yeni P, Young B. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48-week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet. 2012;12:111–8.

    Article  PubMed  Google Scholar 

  79. Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.

    Article  CAS  PubMed  Google Scholar 

  80. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536–48.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Cottrell M, Hadzic T, Kashuba A. Clinical pharmacokinetic, pharmacodynamics and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Reese M, Savina P, Generaux G, Tracey H, Humphreys J, Kanaoka E. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353–61.

    Article  CAS  PubMed  Google Scholar 

  83. Dooley K, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–7.

    Article  CAS  PubMed  Google Scholar 

  84. Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, et al. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol. 2014;70:1173–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Song I, Borland J, Chen S, Patel P, Wajlma T, Peppercorn A, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56(3):1627–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Patel P, Song I, Borland J, Patel A, Lou Y, Chen S, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66:1567–72.

    Article  CAS  PubMed  Google Scholar 

  87. Viani RM, Alvero C, Fenton T, Acosta E, Hazra R, O’Gara E. Safety pharmacokinetics and efficacy of dolutegravir in treatment experienced HIV+ children [abstract no. 119]. 21st Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston.

  88. Eron J, Bonaventura C, Durant J, Katlama C, Kumar P, Lazzarin A, et al. safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the Viking study. J Infect Dis. 2013;207:740–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R. Dolutegravir in antiretroviral-experienced patients with raltegravir and/or elvitegravir resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  90. European Medicines Agency. Tivicay (dolutegravir). 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002753/human_med_001720.jsp&mid=WC0b01ac058001d124. Accessed 2 Jul 2015.

  91. The Medicines Patent Pool (MPP). MPP licences on dolutegravir (DTG). 2014. http://www.medicinespatentpool.org/medicines-patent-pool-viiv-healthcare-sign-licence-for-the-most-recent-hiv-medicine-to-have-received-regulatory-approval/. Accessed 2 July 2015.

  92. University of Liverpool, ViiV Healthcare, Makerere University. Safety and pharmacokinetics of dolutegravir in pregnant HIV mothers and their neonates: a pilot study (DoPHIN1) [ClinicalTrials.gov identifier NCT02245022]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 2 Jul 2015.

  93. National Institute of Allergy and Infectious Diseases (NIAID). Safety and immune response to dolutegravir (GSK1349572) in HIV-1 infected infants, children, and adolescents [ClinicalTrials.gov identifier NCT01302847]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 2 Jul 2015.

  94. National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Pharmacokinetic study of antiretroviral drugs and related drugs during and after pregnancy [ClinicalTrials.gov identifier NCT00042289]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 2 Jul 2015.

  95. Hegazi A, McKeown D, Doerholt K, Donaghy S, Sadiq S, Hay P. Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates. AIDS. 2012;26:2421–2.

    Article  PubMed  Google Scholar 

  96. McKeown D, Rosenvinge M, Donaghy S, Sharland M, Holt D, Cormack I, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24(15):2416–8.

    Article  PubMed  Google Scholar 

  97. Fader L, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, et al. Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCNI) of HIV-1. ACS Med Chem Lett. 2014;5:422–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  98. Karmon S, Mohri H, Spreen W, Markowitz M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J Acquir Immune Defic Syndr. 2015;68(3):e39–341.

    Article  PubMed  Google Scholar 

  99. National Institute of Allergy and Infectious Diseases (NIAID). Safety and pharmacokinetics of raltegravir in HIV-1 exposed newborn infants at high risk of acquiring HIV-1 infection [ClinicalTrials.gov identifier NCT01780831]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 3 Apr 2015.

  100. International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID). Pharmacokinetic effects of new antiretroviral drugs on children, adolescents and young adults [ClinicalTrials.gov identifier NCT00977756]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 3 Apr 2015.

  101. United States Food and Drug Administration. Package insert, dolutegravir. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf. Accessed 3 Apr 2015.

  102. United States National Institutes of Health. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://aidsinfo.nih.gov/contentfiles/lvguidelines/PediatricGuidelines.pdf. Accessed 7 Apr 2015.

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Pediatrics, The University of New Mexico, MSC10 5590, 1 University of New Mexico, Albuquerque, NM, 87131-0001, USA

    Walter Dehority

  2. Department of Pediatrics, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    Jacobo Abadi & Andrew Wiznia

  3. Division of Infectious Diseases, Department of Pediatrics, Rady Children’s Hospital, The University of California San Diego School of Medicine, San Diego, CA, USA

    Rolando M. Viani

Authors
  1. Walter Dehority
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacobo Abadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Wiznia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rolando M. Viani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter Dehority.

Ethics declarations

Funding

This manuscript was not supported by any external funding.

Conflicts of interest

Drs Dehority, Abadi, Wiznia, and Viani have no conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dehority, W., Abadi, J., Wiznia, A. et al. Use of Integrase Inhibitors in HIV-Infected Children and Adolescents. Drugs 75, 1483–1497 (2015). https://doi.org/10.1007/s40265-015-0446-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0446-2

Keywords

Search

Navigation